ArticleAdvances in therapy2025
COVID-19-Related Healthcare Resource Utilisation and Costs in Paediatric Patients in Germany: A Population-Based Study.
Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThere is limited evidence on the economic burden of COVID-19 in Germany. This study aims to quantify healthcare resource utilisation (HCRU) and direct medical costs associated with COVID-19 in paediatrics in Germany.
methodsThis was a population-based retrospective cohort study using data from the German Statutory Health Insurance (SHI) claims database to define outpatient (April 2020 to December 2021) and hospitalised (April 2020 to October 2022) cohorts of paediatric patients (aged 1-17 years) with a COVID-19 diagnosis.
resultsIn the outpatient cohort (n = 104,656), most (77%) patients had ≥ 2 COVID-19-related general practitioner (GP) visits and 29% had ≥ 1 specialist visit during their diagnosis quarter. Outpatient resource use was greater in high-risk patients. When stratified by age, a greater proportion of children aged 1-4 years had ≥ 2 GP consultations, with specialist visits more common in those aged 5-11 years. The median cost per COVID-19 diagnosis quarter per patient was €192. Among the hospitalised cohort (n = 3129), the median general inpatient length of hospital stay (LoS) per patient per admission was 6.0 days; LoS was highest in those aged 5-11 years (7.0 days), at high risk (7.0 days) and during Alpha and Omicron predominance (both 7.0 days). The median cost per admission per patient was €12,503. Admission to critical care was observed in 13%, in whom the median cost per hospitalisation was €21,193.
conclusionsCOVID-19-associated HCRU and costs among the paediatric population in Germany are non-negligible, driven largely by hospitalisations, particularly those who had a critical care admission and were at high risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.